Drug Trial Radar · NCT00490035
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
Last checked: Nov 20, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
399
Actual
Start
Sep 2007
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- UCB Pharma SAUCB
- Sponsor type
- Industry
- First posted
- Jun 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
Conditions
- Epilepsy
Interventions
PlaceboOther
Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
BrivaracetamDrug
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
BrivaracetamDrug
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
BrivaracetamDrug
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment PeriodTime frame: From Baseline to 12-week Treatment Period
Locations
76 sites in 12 countries. Site status is shown where the registry gives one.
13
Ghent, Belgium
19
La Louvière, Belgium
12
Liège, Belgium
10
Sankt Vith, Belgium
44
Kuopio, Finland
41
Oulu, Finland
42
Seinäjoki, Finland
43
Tampere, Finland
60
Angers, France
56
Béthune, France
62
Bron, France
57
Dijon, France
53
Lille, France
52
Montpellier, France
64
Nancy, France
54
Paris, France
51
Rennes, France
61
Roanne, France
55
Strasbourg, France
76
Bad Berka, Germany
73
Berlin, Germany
79
Bernau, Germany
78
Bielefeld, Germany
74
Freiburg im Breisgau, Germany
75
Kehl-Kork, Germany
77
Mainz, Germany
70
München, Germany
72
Radeberg, Germany
71
Ulm, Germany
94
Budapest, Hungary
90
Debrecen, Hungary
92
Pécs, Hungary
256
Bangalore, India
257
Bangalore, India
253
Hyderabad, India
258
Jaipur, India
255
Kolkata, India
250
Lucknow, India
259
Mumbai, India
270
Pune, India
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.